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OBJECTIVES The goal of this study was to determine whether patients with vascular erectile dysfunction
(ED) and no other clinical cardiovascular disease have structural and functional abnormalities
of other vascular beds.
BACKGROUND In many ED patients, vascular disease is the major underlying cause. It may be that ED is an
early marker of atherosclerosis in patients without clinical cardiovascular disease.
METHODS We assessed systemic vascular structure and function in 30 patients with ED and 27
age-matched normal control (NL) subjects. We measured vascular parameters, including: 1)
carotid and brachial artery diameters, intima-media thickness, compliance, and distensibility;
2) aortic pulse wave velocity; 3) coronary calcification; and 4) brachial artery endothelium-
dependent and -independent vasodilation.
RESULTS There were no significant differences in baseline demographics, coronary artery risk score, or
lipid values between the two groups. Most structural and functional vascular parameters were
similar in the ED and NL groups. Brachial artery flow-mediated vasodilation (FMD) (1.3 vs.
2.4%, p  0.014) and vasodilation to nitroglycerin (NTG) (13.0 vs. 17.8%, p  0.05) were
significantly reduced in ED patients, compared with NL subjects. In addition, there was a
significant correlation between FMD and vasodilation to NTG in ED patients (r  0.59, p
 0.05) but not in NL subjects.
CONCLUSIONS Patients with ED but no clinical cardiovascular disease have a peripheral vascular defect in
endothelium-dependent and -independent vasodilation that occurs before the development of
other overt functional or structural systemic vascular disease and is independent of other
traditional cardiovascular risk factors. (J Am Coll Cardiol 2004;43:179–84) © 2004 by the
American College of Cardiology Foundation
Erectile dysfunction (ED) is present in up to 30 million men
in the U.S. and approximately 100 million men worldwide
(1) and affects up to 52% of men between the ages of 40 and
70 years (2,3). It is now recognized that vascular disease of
the penile arteries is the most common cause of ED,
accounting for up to 80% of cases (4–6). The nitric
oxide–cyclic guanosine-35-monophosphate (NO-cGMP)
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system is important in producing the arterial and venous
dilation necessary to attain and sustain an erection. Abnor-
malities of this vasodilator system are present in atheroscle-
rosis and play an important role in the pathophysiology of
ED (7–9). In addition, drugs such as sildenafil, which serve
to enhance vasodilation by inhibiting the breakdown of
cGMP, are very effective in treating ED (1).
Most previous clinical studies of ED have focused on
patients with multiple risk factors for atherosclerosis or
patients with known cardiovascular disease (5,6,10). These
studies have led to the perception that ED is a disease of
patients with advanced atherosclerosis. However, we have
observed that many relatively young patients presenting
with ED do not have clinical cardiovascular disease or major
risk factors for atherosclerosis. We hypothesize that these
patients have systemic vascular disease and that ED is the
first clinical manifestation of this disease. The present study
was thus designed to determine whether patients with ED
and no other clinical cardiovascular disease have structural
and functional abnormalities in other vascular beds.
METHODS
Study groups. Thirty patients with ED and 27 age-
matched normal control (NL) subjects were recruited from
a sexual dysfunction urology clinic and from newspaper
advertisements. All subjects were without a clinical history
or physical examination providing evidence of cardiovascu-
lar disease. Exclusion criteria for ED patients and NL
subjects included recent smoking history (previous five
years), known hypertension, hyperlipidemia, and diabetes
mellitus. Patients with neurogenic causes of ED were
excluded based on their history and physical examination.
Patients with psychiatric causes of ED were excluded based
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on a psychosocial questionnaire that assessed performance
anxiety, stress, depression, and relationship issues.
Study protocol. Patients with ED underwent a urologic
evaluation and penile Doppler examination to exclude
nonvascular causes of ED. All subjects then underwent a
series of tests, including a blood draw, ED questionnaire,
and measurement of vascular parameters: 1) coronary calci-
fication; 2) aortic pulse wave velocity (PWV); 3) brachial
and carotid artery diameters, intima-media thickness
(IMT), compliance, and distensibility; and 4) brachial artery
endothelium-dependent and -independent vasodilation.
The ED questionnaire response was also measured after two
months or more of 50 mg oral sildenafil therapy to deter-
mine whether therapy designed to improve the NO-cGMP
system would successfully improve the symptoms of ED in
these patients.
Penile Doppler examination. Penile Doppler studies were
performed in the ED group only, using the Knoll/Midus
ultrasonic velocitometric system (Urometrics, St. Paul,
Minnesota). This system incorporates a penile ultrasonic
velocitometer that uses two moveable, fixed-angle, 8-MHz
transducers to measure cavernosal artery velocity as an
indicator of penile blood flow. Measurements using this
system have previously correlated well with duplex ultra-
sonography with respect to peak systolic velocity (PSV),
end-diastolic velocity (EDV), and resistance index (RI 
[PSV  EDV]/PSV) (11). All ED patients received 10 to
20 g of intracavernosal prostaglandin E1 (PGE1; Caver-
ject, Pharmacia, New Jersey), and measurements were
performed at 5 and 15 min after injection to determine the
PSV, EDV, and RI. Erectile dysfunction was determined to
be vascular in origin if PSV was 35 cm/s or RI was 0.9
(12,13).
Blood tests. The following laboratory tests were per-
formed: fasting lipid panel (low-density lipoprotein [LDL]
cholesterol, high-density lipoprotein [HDL] cholesterol,
triglycerides, total cholesterol), lipoprotein(a), fasting glu-
cose, and homocysteine. For each participant, fasting blood
samples were drawn into a serum tube and an EDTA-
containing tube that were separated within 30 min. Serum
and plasma aliquots were frozen immediately at 70°C
until analyzed. Cholesterol, triglycerides, HDL cholesterol,
and glucose were measured in serum by colorimetric reflec-
tance spectrophotometry, using the Vitros analyzer (John-
son & Johnson Clinical Diagnostics, Inc., Rochester, New
York). For HDL cholesterol, the non-HDL cholesterol was
first precipitated with magnetic 50,000 molecular weight
dextran sulfate and magnesium chloride. The LDL choles-
terol was calculated in serum with a triglyceride value
400 mg/dl, using the formula of Friedewald et al. (14).
Fasting homocysteine was measured in EDTA plasma by a
fluorescence polarization immunoassay (IMx homocysteine
Assay, Axis Biochemicals ASA, Oslo, Norway), using the
Imx Analyzer (Abbott Diagnostics, Abbott Park, Illinois).
The ED questionnaire. The 15-item International Index
of Erectile Function (IIEF-15), a validated, self-
administered questionnaire, was used for the clinical assess-
ment of ED (15,16). In this questionnaire, symptoms of ED
are assessed in five domains, with each domain having a
maximum score of 5.
Aortic PWV. Pulse wave velocity was measured along the
descending thoraco-abdominal aorta using the foot-to-foot
velocity method, as previously published and validated
(17,18). Briefly, waveforms were obtained transcutaneously
over the common carotid artery and right femoral artery,
and the time delay (t) was measured between the feet of the
two waveforms. The distance (D) covered by the waves was
measured between the two recording sites. Thus, PWV was
calculated as: PWV  D (m)/t (s). The mean  SD
difference between PWV measurements obtained 5 min
apart was 0.18  1.47 m/s (p  NS).
Coronary calcification. Electrocardiographically gated he-
lical computed tomography (GE Multislice Lightspeed, GE
Medical Systems, Milwaukee, Wisconsin) was used for
noninvasive quantification of coronary artery calcium (19).
The image acquisition consisted of a scan from the base of
the heart to the apex, using cine loops of 4 slices, 11
images/slice, and a slice thickness of 2.5 mm. The rotation
time was 0.8 s, with 0.1 s between images. The field of view
was 25 cm, with a 512  512 matrix size. Image processing
was performed with SmartScore (GE Medical Systems),
using the conventional Agatston method with a threshold of
130 Hounsfield units. A coronary calcium score 5 was
considered abnormal.
Brachial and carotid artery mechanical properties.
Arterial diameter, change in diameter (D), and IMT were
imaged using a wall-tracking system (PIE Medical WTS
V2, Maastricht, The Netherlands), with a 10.0-MHz linear
array ultrasound transducer held in place by a stereotactic
device (20). The system consists of software running on a
standard personal computer equipped with a data acquisi-
tion card for the acquisition of radiofrequency ultrasound
signals obtained with a conventional echo scanner (Bio-
sound AU5). Arterial pressure, diameter, D, and IMT of
Abbreviations and Acronyms
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ED  erectile dysfunction
EDV  end-diastolic velocity
FMD  flow-mediated vasodilation
HDL  high-density lipoprotein
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Function
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PGE1  prostaglandin E1
PSV  peak systolic velocity
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the brachial artery were measured with the subject resting in
the supine position. The nondominant arm was fixed level
with the heart at an angle of 45° from the head to feet axis
and supported by a tilt-table arm brace. An arterial pressure
waveform was obtained using a tonometer placed over the
radial artery and calibrated to a standard blood pressure cuff
placed on the contralateral arm (Colin Medical, San Anto-
nio, Texas). The diameter, D, and IMT of the carotid
artery were measured with the subject resting in the supine
position with the head turned 45° from the side being
scanned. The reference point for measurement of the
carotid artery was at the common carotid artery 2 cm
proximal to the beginning of the dilation of the bulb (21).
Compliance was defined as the change in area (A) for a
given change in pressure (P). Distensibility was defined as
the compliance divided by the vessel area in diastole:
(A/P)/A. The final values reported for all mechanical
properties were the average of three measurements. Repro-
ducibility of diameter, D, and IMT were assessed using
the Bland-Altman technique (22). The mean  SD differ-
ences between brachial artery diameter, D, and IMT
measurements obtained 5 min apart were 0.005  0.188
mm, 0.6  17.8 m, and 0.01  0.06 mm, respectively
(p  NS). The mean  SD differences between carotid
artery measurements obtained 5 min apart were 0.120 
0.388 mm, 19.3  75.3 m, and –0.02  0.15 mm for
diameter, D, and IMT, respectively (p  NS).
Brachial artery endothelium-dependent and -independent
vasodilation. Assessment of brachial artery vasodilation
was done using the ultrasound system described earlier.
Arterial diameter was recorded over time, as previously
shown (23,24). Endothelium-dependent, flow-mediated
vasodilation (FMD) was produced by releasing a blood
pressure tourniquet around the wrist, which was inflated for
5 min at a pressure of 250 mm Hg (25,26). The diameter
was tracked over time, beginning 10 s before cuff release and
lasting 	90 s. Endothelium-dependent vasodilation was
expressed as the percent change from the diameter imme-
diately after cuff deflation to the diameter at 60 s after cuff
deflation. The mean  SD percent differences between the
diameter before cuff inflation and the diameter immediately
after cuff deflation were 0.5  5.7% and 0.2  4.6% for
the NL and ED groups, respectively (p  NS). The
short-term mean  SD relative difference in FMD mea-
sured 10 min apart was 0.15  2.49% (p  NS). In a
subgroup of 38 individuals, the mean  SD relative differ-
ences in measurements made an average of 130  43 days
apart were 0.117  0.346 mm for baseline diameter and
0.42  1.50% dilation for FMD (p NS). After a 10-min
rest, 0.4 mg sublingual nitroglycerin (NTG) was adminis-
tered, and the diameter of the brachial artery was measured
three times at 5 min after administration. Endothelium-
independent vasodilation was defined as the percent change
from resting baseline to the average of the three post-NTG
diameters. The dose used has previously been shown to
cause maximum vasodilation (27).
Statistical analysis. Statistical analysis was performed us-
ing SPSS version 8.0. Demographic data, blood tests, and
vascular measures were assessed using the unpaired t test.
Brachial artery endothelial function curves for ED patients
and NL subjects were compared using two-way analysis of
variance, with group as a fixed factor and time as a repeated
measures factor. Simple linear regression was used to assess
the relationship between endothelium-dependent and
-independent vasodilation within the two groups. Statistical
significance was defined as p 0.05. Data in the figures and
tables are presented as the mean value  SEM.
RESULTS
Table 1 shows the baseline characteristics of the 30 patients
with ED and the 27 NL subjects. Heart rate was signifi-
cantly increased in the ED group. There were no other
significant differences in baseline demographics between the
two groups. The Framingham cardiac risk score for coro-
nary artery disease (CAD) tended to be slightly higher in
the NL subjects, but this trend was not statistically signif-
icant. The patients with ED had objective evidence of
significant clinical and penile vascular disease. Mean PSV
measured by penile Doppler was 28  3 m/s (normal
35 m/s). The mean  SD IIEF-15 score was 13.7  6.5
in the ED group versus 21.3  5.3 in the NL group (p 
0.0001), indicative of moderate symptoms of ED. The
mean IIEF score increased by 3  5 after two months or
more of sildenafil therapy (p  0.001).
Table 2 shows blood tests and vascular study results for
the two groups of subjects. Lipid values were similar in the
two groups. Structural vascular parameters, including coro-
nary calcium score, carotid and brachial artery diameters,
and IMT, were similar between the two groups. Functional
vascular parameters, including brachial and carotid artery
compliance and distensibility and aortic PWV, were similar
between the two groups.
Figure 1 shows the mean FMD curves for the ED and
NL groups. Brachial artery FMD was significantly reduced
in ED patients versus NL subjects, whether comparing over






Age (yrs) 46.2  2.4 46.6  1.7
BMI (kg/m2) 27.6  1.2 28.4  1.0
Systolic pressure (mm Hg) 124.2  2.8 123.1  2.5
Diastolic pressure (mm Hg) 72.6  1.9 72.9  1.8
Mean pressure (mm Hg) 87.8  2.9 89.2  1.9
Pulse pressure (mm Hg) 51.6  1.7 50.2  1.9
Heart rate (beats/min) 60  1.3 64  1.6*
CAD score 3.2  0.8 3.5  0.6
Penile Doppler PSV (m/s) — 28  3
IIEF-15 21.3  1.2 13.7  1.2†
*p  0.05. †p  0.01. Data are presented as the mean  SEM.
BMI  body mass index; CAD  coronary artery disease by Framingham cardiac
risk score; ED  erectile dysfunction; IIEF-15  15-item International Index of
Erectile Function questionnaire; NL  normal control; PSV  peak systolic velocity.
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the entire 90-s period after cuff release (1.3  0.3% vs.
2.4  0.3%, p  0.014) or at 60 s after cuff release (2.4 
0.5% vs. 3.7  0.5%, p  0.05). The maximum response to
0.4 mg sublingual NTG was significantly impaired in ED
patients versus NL subjects (13.0  1.4% vs. 17.8  1.4%,
p  0.02) (Fig. 2). In addition, there was a significant
correlation between FMD and vasodilation to NTG in ED
patients (r  0.59, p  0.05) but not in NL subjects (r 
0.05, p  NS) (Fig. 3).
DISCUSSION
The main finding of this study is that patients with ED and
no significant cardiac risk factors or other clinical cardio-
vascular disease have a peripheral vascular abnormality in
the NO-cGMP pathway, as measured by brachial artery
FMD and vasodilation to sublingual NTG. Flow-mediated
vasodilation has previously been shown to be largely medi-
ated by NO (28). This impairment in brachial artery
endothelial-dependent and -independent vasodilation is
present despite a normal CAD risk score, normal systemic
vascular stiffness measures (compliance, distensibility, and
PWV), and normal systemic vascular structure (diameter,
IMT, coronary calcium score). These data suggest that an
abnormality in the peripheral vascular NO-cGMP vasodi-
lator system may result in ED as the first clinical manifes-
tation of cardiovascular disease.
It is well known that patients with risk factors for
cardiovascular disease or overt cardiovascular disease are at
risk of developing ED. In one study, 64% of men who
presented with myocardial infarction reported symptoms of
ED before their heart problems, and in another study, 57%
of men undergoing coronary artery bypass graft surgery
Figure 1. Brachial artery flow-mediated vasodilation (FMV) was signifi-
cantly reduced in erectile dysfunction patients (circles) versus normal
control subjects (squares) over the whole time period (p  0.014). The
difference was also significant when comparing the percent dilation from
baseline to 60 s after cuff release (p  0.05). * denotes a significant increase
compared to erectile dysfunction over the entire curve.
Figure 2. The vasodilator response to 0.4 mg sublingual nitroglycerin
(NTG) was significantly impaired in erectile dysfunction (ED) patients
versus normal control subjects (13.0  1.4% vs. 17.8  1.4%, p  0.02).
* denotes a significant decrease compared to normal.






Total cholesterol (mg/dl) 193.1  8.6 203.6  7.6
Triglycerides (mg/dl) 130.7  18.4 115  11.5
HDL cholesterol (mg/dl) 47.9  3.9 47.7  2.4
LDL cholesterol (mg/dl) 118.5  7.0 128.2  6.8
Lipoprotein(a) (mg/dl) 24.3  10.3 22.4  3.7
Glucose (mg/dl) 92.9  2.1 90.0  1.6
Homocysteine (mg/dl) 9.2  0.3 8.9  0.5
Vascular results
Coronary calcium (% with score 5) 20% 27%
PWV (m/s) 7.9  0.3 7.8  0.4
Carotid (baseline)
Compliance (mm2/mm Hg) 111.3  9.1  103 100.6  8.0  103
Distensibility (mm Hg1) 2.67  0.20  103 2.47  0.17  103
Diameter (mm) 7.30  0.17 7.14  0.16
IMT (mm) 0.62  0.03 0.65  0.03
Brachial (baseline)
Compliance (mm2/mm Hg) 9.4  1.0  103 9.2  1.0  103
Distensibility (mm Hg1) 0.58  0.04  103 0.54  0.04  103
Diameter (mm) 4.48  0.11 4.59  0.13
IMT (mm) 0.40  0.01 0.41  0.01
Data are presented as the mean value  SEM.
HDL  high-density lipoprotein; IMT  intima-media thickness; LDL  low-density lipoprotein; PWV  pulse wave
velocity measured at carotid and femoral arteries; other abbreviations as in Table 1.
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reported ED symptoms before the operation (29). In these
patients, ED was an early, or perhaps initial, clinical
manifestation of atherosclerotic vascular disease. These
studies raise the possibility that ED may serve as a clinical
marker for the presence of future vascular disease or adverse
cardiac events. However, there are little data available on the
vasculature of patients with ED but no other clinical
cardiovascular disease.
The patients with ED evaluated in this study clearly had
a vascular etiology for their symptoms, as they had abnormal
penile Doppler studies. They likely had impairment in the
penile NO-cGMP system, because sildenafil treatment
resulted in significant improvement in symptoms of ED.
The finding of impaired endothelium-dependent and
-independent vasodilation in patients with ED is similar to
that found in patients with hypercholesterolemia (30) and
early atherosclerosis (31). The abnormality noted in this
study of ED patients could not be attributed to the presence
of traditional cardiovascular risk factors, because the pa-
tients with ED were no different from the control subjects
with respect to blood pressure, baseline lipid values, pres-
ence of diabetes mellitus, smoking status, and CAD risk score.
Risk factors such as LDL particle size, high-sensitivity
C-reactive protein, plasminogen activator inhibitor-1, and
measures of oxidative stress (among others) were not mea-
sured and could possibly have contributed to the differences
in vasodilation. The ED patients in this study were over-
weight, with a body mass index of 28.4  1.0. We did not
measure glucose tolerance or insulin sensitivity, so we
cannot exclude the presence of abnormalities of these
parameters in our ED patients. However, the NL subjects
were similarly overweight, with a body mass index of 27.6
1.2, so this potential risk factor is unlikely to account for the
differences in vasodilation observed in this study.
The abnormality in the NO-cGMP system likely con-
tributing substantially to ED was also present in the brachial
artery. This abnormality appears to be a relatively early
marker of atherosclerotic arterial disease, because other
functional and structural parameters of three different sys-
temic arteries were normal. There are several potential
explanations for the presence of clinically significant vascu-
lar disease in the penile vascular bed before the presence of
overt atherosclerotic vascular disease in other arteries. Penile
arteries are relatively small, with the average cavernosal
artery 0.5 mm in diameter, and helicine arteries, which run
between the cavernosal artery and the sinusoids, are much
smaller. These smaller arteries need to dilate up to 80% to
provide the blood flow necessary to produce enough venous
compression to sustain erection (32). This contrasts with
other conduit arteries that dilate up to about 15% during
FMD. In addition, the penile vascular bed is dependent on
NO for vasodilation of arteries to produce rapid blood
inflow, as well as for vasodilation of trabeculae smooth
muscle of the lacunar spaces to prevent venous outflow. The
relaxation of the lacunae and filling with arterial blood
under high pressure cause the lacunae to swell and press the
penile drainage veins against the resistant tunica albuginea,
thus trapping the blood in the penis. In many other vascular
beds, the role of NO on the venous side of the circulation is
minimal. This high degree of dependence on NO for both
normal and rapid arterial inflow and for prevention of
venous outflow may account for the increased susceptibility
of this vascular bed to deficiencies in the NO-cGMP
vasodilator system.
Two stimuli of the NO-cGMP vasodilator system were
assessed in this study: shear stress-induced FMD and NTG.
Brachial artery vasodilation to both of these stimuli was
abnormal in the patients with ED. The defect in the
NO-cGMP vasodilator pathway must involve the smooth
muscle, because vasodilation to the direct smooth muscle
dilator NTG was impaired in the brachial artery of the
patients with ED. There may also be a defect in endothelial
NO bioavailability. However, the correlation between the
vasodilator response to flow and NTG in ED patients
suggests that the predominant defect in this vasodilator
system is not in the endothelium.
It is unknown whether patients with ED have a specific
defect in one vasodilator pathway or whether several path-
way defects exist. We did not test other vasodilator stimuli
in the peripheral vasculature of ED patients. However, we
did demonstrate abnormal penile blood flow in response to
intracavernosal PGE1, a vasodilator that works via increas-
ing smooth muscle cyclic adenosine monophosphate
(cAMP) levels. This test does not necessarily imply a
specific defect in cAMP-mediated vasodilation, as the
vasodilator response to PGE1 may, in large part, depend on
FMD as a result of endothelial NO release. One previous
study showed that cGMP-dependent kinase I–deficient
mice failed to relax corpora cavernosa smooth muscle on
activation of the NO-cGMP signaling cascade (33). How-
ever, vasodilation remained intact via the cAMP-mediated
pathway in these mice.
The FMD responses in our NL subjects are lower in our
study than in some other laboratories’ reports. This was
because our technique for measuring FMD uses a wrist
occlusion cuff instead of a forearm occlusion cuff to create
the reactive hyperemic flow stimulus for FMD. This results
Figure 3. There was a significant correlation between endothelium-
dependent (flow-mediated vasodilation) and -independent (nitroglycerin
[NTG]) vasodilation in erectile dysfunction patients (circles) (r  0.59, p
 0.05) but not in normal control subjects (squares) (r  0.05, p  NS).
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in a lower peak and total reactive hyperemia and thus a
lower vasodilator response to flow. Our values for FMD are
similar to those measured in other laboratories that use a
wrist occlusion technique (34) and are consistent with
normal endothelial function in our NL subjects.
Conclusions. This study demonstrates a defect in the
peripheral vascular NO-cGMP system in patients with ED
but no other clinical cardiovascular disease. This defect is
predominantly in the smooth muscle and can occur before
the development of other overt functional or structural
systemic vascular disease. In addition, this abnormality in
the patient population studied is not associated with tradi-
tional cardiovascular risk factors. Erectile dysfunction can be
an early clinical marker for the presence of systemic vaso-
dilator abnormalities. It remains to be seen whether patients
with ED and abnormal NO-cGMP–mediated vasodilation
will progress to clinically significant systemic cardiovascular
disease or go on to have acute cardiovascular events such as
stroke or myocardial infarction.
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